Genta and Aventis Terminate Genasense® Agreements

12-May-2005

Genta Incorporated announced that Genta and Aventis, part of the sanofi-aventis Group, have signed an agreement to terminate their development and commercialization collaboration for Genasense® (oblimersen sodium injection). On November 8 2004, Aventis had provided Genta notice of termination of the Genasense agreements.

The termination agreement provides no future financial obligations by either party, and the line of credit established by Aventis to Genta will be retired. Aventis will also return its current inventory of Genasense drug supply to Genta. In addition, Genta will assume responsibility for the randomized clinical trial of Genasense in combination with docetaxel (Taxotere®; sanofi-aventis) in patients with hormone-refractory prostate cancer, which is currently ongoing in Europe.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances